Bayer A.G.

7.87

+0.20002.61%

Volume:463.93K

Turnover:3.65M

Market Cap:30.93B

PE:-8.77

High:7.93

Open:7.82

Low:7.79

Close:7.67

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BAYRY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.87,"timestamp":1751054400000,"preClose":7.67,"halted":0,"volume":463934,"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Market Closed","change":0.2,"latestTime":"06-27 16:00:00 EDT Delay","open":7.82,"high":7.93,"low":7.79,"amount":3651859.3794000074,"amplitude":0.018253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.67,"volumeRatio":0.8578880156652624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":0.8578880156652624,"shares":3929696328,"dividePrice":0.030365,"high":7.93,"amplitude":0.018253,"preClose":7.67,"low":7.79,"week52Low":4.79,"pbRate":"0.81","psRate":"0.57","week52High":8.58,"institutionHeld":0,"latestPrice":7.87,"eps":-0.897103,"divideRate":0.003858,"volume":463934,"delay":15,"ttmEps":-0.897103,"open":7.82,"prevYearClose":4.88,"prevWeekClose":7.68,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.68,"twentyDayClose":7.06,"sixtyDayClose":6.05},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BAYRY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544512640","title":"Orion says Bayer reports CHMP recommends third indication for darolutamide","url":"https://stock-news.laohu8.com/highlight/detail?id=2544512640","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544512640?lang=en_us&edition=fundamental","pubTime":"2025-06-20 18:35","pubTimestamp":1750415732,"startTime":"0","endTime":"0","summary":"Orion’s (ORINY) collaboration partner Bayer (BAYRY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Age...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/orion-says-bayer-reports-chmp-recommends-third-indication-for-darolutamide-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/orion-says-bayer-reports-chmp-recommends-third-indication-for-darolutamide-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","ORINY","BAYRY","BK4007","CHMP"],"gpt_icon":0},{"id":"2544999175","title":"Bayer Files for FDA Approval of Gadoquatrane","url":"https://stock-news.laohu8.com/highlight/detail?id=2544999175","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544999175?lang=en_us&edition=fundamental","pubTime":"2025-06-17 23:49","pubTimestamp":1750175340,"startTime":"0","endTime":"0","summary":"Bayer submitted a new drug application for approval of its contrast agent gadoquatrane to the Food and Drug Administration.The German life-sciences company said Tuesday the agent provides contrast-enhanced magnetic resonance imaging of the central nervous system and other body regions in adults and pediatric patients, including newborns.The company's application included a submitted dose of 0.04 millimole gadolinium per kilogram of body weight. If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based contrast agent available in the U.S., Bayer said.The submission is based on positive data from Phase III studies evaluating the efficacy and safety of gadoquatrane in adult and pediatric patients, the company said.Patients, especially those with chronic conditions who require multiple contrast-enhanced MRI examinations during their lifetime, can benefit from a reduced gadolinium dose, according to Dr. Konstanze Diefenbach, Bayer's head of radiology research and d","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2542171306","title":"Bayer upgraded to Buy from Hold at Kepler Cheuvreux","url":"https://stock-news.laohu8.com/highlight/detail?id=2542171306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542171306?lang=en_us&edition=fundamental","pubTime":"2025-06-11 16:35","pubTimestamp":1749630907,"startTime":"0","endTime":"0","summary":"Kepler Cheuvreux upgraded Bayer (BAYRY) to Buy from Hold with an unchanged price target of EUR 33. All of Bayer’s operational problems and a “good ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-upgraded-to-buy-from-hold-at-kepler-cheuvreux-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-upgraded-to-buy-from-hold-at-kepler-cheuvreux-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2541551042","title":"Bayer Earnings Expectations Might Have Bottomed out -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2541551042","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541551042?lang=en_us&edition=fundamental","pubTime":"2025-06-05 16:29","pubTimestamp":1749112140,"startTime":"0","endTime":"0","summary":"0829 GMT - Bayer's strong start to the year and signs of a recovery in its pharmaceutical business suggests earnings expectations might have bottomed out, Goldman Sachs analysts say in a research note. Consensus earnings estimates on the German agricultural and pharma group could start to trend higher as the market gives credit to its cost-savings plan, the analysts say. Moreover, the risk-reward equation on litigation updates through 2025 looks more favorable, according to Goldman Sachs. Legal cases over Bayer's Roundup weedkiller have been a drag on its stock since it lost the first trial in 2018, the analysts say. Goldman Sachs raises its recommendation on Bayer to buy from neutral, and lifts its target price to 33 euros from 29.10 euros. Shares jump 4.9% to 26.55 euros. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0}],"pageSize":4,"totalPage":17,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}